Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A-dmDT390-bisFv(UCHT1) + pembrolizumab
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A-dmDT390-bisFv(UCHT1) + pembrolizumab is an investigational combination therapy comprised of a recombinant fusion toxin protein (A-dmDT390-bisFv(UCHT1)) and a monoclonal antibody immune checkpoint inhibitor (pembrolizumab). A-dmDT390-bisFv(UCHT1) is a fusion protein composed of a truncated diphtheria toxin (DT390) linked to two single-chain variable fragments (bisFv) derived from the anti-CD3 monoclonal antibody UCHT1. It targets CD3 on T cells, delivering the toxin to induce cell death. Pembrolizumab is an anti-PD-1 monoclonal antibody that blocks programmed death receptor-1, releasing inhibition of T-cell–mediated immune responses against tumors. The combination is being studied for synergistic anti-tumor activity by promoting T cell killing and releasing immune checkpoint inhibition. The primary indication under investigation is oncology, particularly advanced solid tumors and lymphoid malignancies.
- Other names
- A-dmDT390-bisFv(UCHT1) + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on A-dmDT390-bisFv(UCHT1) + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A-dmDT390-bisFv(UCHT1) + pembrolizumab.